Patrick Tricoli was appointed in 2014 Chief Executive Officer of Nanobiotix Corp., the Nanobiotix US affiliate in Cambridge, MA focused on building the Nanobiotix US presence while cultivating cross-industry relationships. Additionally, and since 2020, he has been leading and implementing the partnering strategy and deal making as Global Head of Business Development at Nanobiotix. Prior to Nanobiotix, Patrick was well known for his lead roles at Sanofi in Partnering and Innovation R&D and subsequently as Head of External Innovation Europe, spanning 15 years, Europe, Asia, and the US markets. He led multiple international teams while he developed strong international business development relationships, corporate development strategies, collaborative R&D partnerships, and business opportunities. He started his career in Neuropharmacology research in both academia in Europe and in the industry at Lederle, now Pfizer in the US.
Since 2017, he has served as a New England Foreign Trade Advisor for the French government and is a board member since 2022. Patrick holds a PharmD, a Master’s degree in Pharmacology and Pharmacokinetic and an Executive MBA from ESCP Europe.

Thierry co-founded Astorg in 1998 and currently leads the organisation. He is a Member of the Group Executive Committee and of the Investment Committee. Prior to this, Thierry spent 4 years with the private equity team at Suez. He began his career in 1989 at Banque Indosuez where he held several positions in London and Paris, particularly in the project finance division.

Thierry graduated from ESCP Europe.

If we had to summarize in a few words Philippe Guerret’s atypical career path until the creation of M2i Group in 2012, we could talk about experimentation and quick responsibilities: development of PepsiCo in France, management of audiovisual rights at UGC Cinema Corp at the time of the takeover by the TV channel Canal+, IPO of Vinci and launch of airport concessions of the group, everything even before its 30th anniversary. Philippe Guerret surfed between Miami and Switzerland, exceled in the repositioning of companies in difficulty, and then specialized in duty free. With a head start, he imagined what could become his next playgroundand fell in love at first sight with the industry through the management of an industrial group producing active pharmaceutical ingredients. Finally, convinced that innovation and industry must go hand in hand, he created M2i Group with 3 partners, including Gilles Rubinstenn. The company, expert in complex molecules historically used for human health, diversified under Philippe Guerret’s leadership towards the production of innovative finished products with high added value for the biological crop treatment as an alternative to pesticides.  In 10 years, after €60 millions raised, M2i hires  200 employees and has become the European leader in its sector by protecting more than 100,000 hectares worldwide.  Philippe is  graduated from EDHEC and is a member of the school’s ETHICS BOARD.

Dr. Krystal is McNeil Professor and Chair of Psychiatry at Yale and Yale-New Haven Hospital. He studies the neurobiology and treatment of psychiatric disorders. His laboratory discovered the rapid antidepressant effects of ketamine. He directs the Yale Center for Clinical Investigation, Center for the Translational Neuroscience of Alcohol, and Neuroscience Division of the National Center for PTSD. He is a member of the National Academy of Medicine; Fellow of the American Association for the Advancement of Science; co-director of the Neuroscience Forum of the National Academies of Sciences, Engineering, and Medicine; editor of Biological Psychiatry; and co-founder of Freedom Biosciences.

Barbara Olasov Rothbaum, PhD is Director of the Emory Healthcare Veterans Program. She is a professor and Associate Vice Chair of Clinical Research at Emory School of Medicine in the Department of Psychiatry and Behavioral Sciences and Director of the Trauma and Anxiety Recovery Program and holds the Paul A. Janssen Chair in Neuropsychopharmcology. She specializes in research on the treatment of anxiety disorders, particularly PTSD. Dr. Rothbaum has been studying PTSD treatments since 1986, served on the DSM-IV PTSD subcommittee, and has developed, tested, and disseminated some of the most innovative and effective treatments available for PTSD. She is an inventor of virtual reality exposure therapy. She was a pioneer in applying it in the treatment of PTSD in combat veterans. Dr. Rothbaum has been conducting translational research on MDMA for almost a decade. She has authored over 400 scientific papers and chapters, has published 11 books on the treatment of PTSD and edited 4 others on anxiety, and received the Diplomate in Behavioral Psychology from the American Board of Professional Psychology. She is a past president of the International Society of Traumatic Stress Studies (ISTSS). She is a fellow of the ACNP, the National Academy of Inventors, the Association for Behavioral and Cognitive Therapies, and American Psychological Association’s Division 56 and was awarded the 2010 “Award for Outstanding Contributions to the Practice of Trauma Psychology” for APA Division 56 and the Robert S. Laufer Award for Outstanding Scientific Achievement from the International Society for Traumatic Stress Studies (ISTSS). Dr. Rothbaum received the 2021 ISTSS the Lifetime Achievement Award. Her recent books on PTSD for the general public: PTSD: What Everyone Needs to Know and Making Meaning of Difficult Experiences.

Dr Bernard Scatton is a biochemical engineer graduated from the National Institute for Applied Sciences in Lyon and holds a PhD in Neurosciences obtained at the College de France in Paris. He joined the pharmaceutical company Rhone-Poulenc in 1970, then Synthelabo and finally Sanofi where he held the position of vice-president of Discovery Research. He led multiple teams in several research centers world while. He has published more than 400 papers in scientific journals and books. His scientific interests were manifold, but he was particularly involved in research and discovery of benzodiazepine receptor agonists for the treatment of sleep disorders and of NMDA receptor antagonists for the treatment of stroke and brain trauma. He is currently retired and consultant in drug development for the pharmaceutical industry, especially start-up companies.